NL301245I2 - Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout - Google Patents

Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Info

Publication number: NL301245I2
Authority: NL; Netherlands
Prior art keywords: ritlecitinib; optionally; pharmaceutically acceptable; acceptable salt; salt
Prior art date: 2013-12-05

Application number

NL301245C

Other languages

English (en)

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-05

Filing date

2023-10-03

Publication date

2023-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52144776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301245(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2023-10-03 Application filed by Pfizer filed Critical Pfizer

2023-11-20 Publication of NL301245I2 publication Critical patent/NL301245I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Psychology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)

NL301245C 2013-12-05 2023-10-03 Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout NL301245I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361912074P	2013-12-05	2013-12-05
PCT/IB2014/066202 WO2015083028A1 (en)	2013-12-05	2014-11-20	Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

Publications (1)

Publication Number	Publication Date
NL301245I2 true NL301245I2 (nl)	2023-11-20

Family

ID=52144776

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301245C NL301245I2 (nl)	2013-12-05	2023-10-03	Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Country Status (47)

Country	Link
US (4)	US9617258B2 (nl)
EP (2)	EP3318565B1 (nl)
JP (2)	JP6192839B2 (nl)
KR (1)	KR101930603B1 (nl)
CN (2)	CN106061973B (nl)
AP (1)	AP2016009269A0 (nl)
AR (1)	AR099363A1 (nl)
AU (1)	AU2014358792C1 (nl)
BR (1)	BR112016012262B1 (nl)
CA (1)	CA2932425C (nl)
CL (1)	CL2016001216A1 (nl)
CR (1)	CR20160250A (nl)
CU (1)	CU24396B1 (nl)
CY (3)	CY1119778T1 (nl)
DK (2)	DK3077395T3 (nl)
DO (1)	DOP2016000124A (nl)
EA (1)	EA030472B1 (nl)
ES (2)	ES2654051T3 (nl)
FI (1)	FIC20230035I1 (nl)
FR (1)	FR23C1042I2 (nl)
GE (1)	GEP20186840B (nl)
GT (1)	GT201600098A (nl)
HR (2)	HRP20171846T1 (nl)
HU (3)	HUE054560T2 (nl)
IL (1)	IL246038B (nl)
LT (3)	LT3077395T (nl)
MA (1)	MA39092B1 (nl)
MD (1)	MD4649C1 (nl)
ME (1)	ME02883B (nl)
MX (1)	MX368464B (nl)
MY (1)	MY187446A (nl)
NI (1)	NI201600075A (nl)
NL (1)	NL301245I2 (nl)
NO (2)	NO3134430T3 (nl)
NZ (1)	NZ720092A (nl)
PE (1)	PE20161246A1 (nl)
PH (1)	PH12016500938A1 (nl)
PL (2)	PL3077395T3 (nl)
PT (2)	PT3318565T (nl)
RS (2)	RS61897B9 (nl)
SI (2)	SI3077395T1 (nl)
SV (1)	SV2016005209A (nl)
TN (1)	TN2016000227A1 (nl)
TW (1)	TWI548636B (nl)
UA (1)	UA117040C2 (nl)
UY (1)	UY35861A (nl)
WO (1)	WO2015083028A1 (nl)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2924362C (en) *	2013-09-18	2018-12-18	Beijing Hanmi Pharmaceutical Co., Ltd.	Compound inhibiting activities of btk and/or jak3 kinases
EP3318565B1 (en) *	2013-12-05	2021-04-14	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
CN105777756B (zh) *	2014-07-02	2019-03-01	广东东阳光药业有限公司	杂芳化合物及其在药物中的应用
SG11201701315VA (en)	2014-08-28	2017-03-30	Asceneuron Sa	Glycosidase inhibitors
CN105712998B (zh) *	2014-12-05	2019-12-13	上海润诺生物科技有限公司	氮杂吲哚类衍生物、其制备方法及其在医药上的应用
AU2016209046A1 (en) *	2015-01-23	2017-07-20	Aclaris Therapeutics, Inc.	Heterocyclic ITK inhibitors for treating inflammation and cancer
CN105837574B (zh) *	2015-02-02	2018-03-02	四川大学	N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
ES2928757T3 (es) *	2015-05-01	2022-11-22	Pfizer	Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa
DK3305788T3 (da) *	2015-05-29	2020-09-28	Wuxi Fortune Pharmaceutical Co Ltd	Janus-kinase-hæmmer
CN106432246B (zh) *	2015-08-05	2020-07-07	广东东阳光药业有限公司	杂芳化合物及其在药物中的应用
KR101771219B1 (ko) *	2015-08-21	2017-09-05	양지화학 주식회사	야누스 키나제 1 선택적 억제제 및 그 의약 용도
UA123633C2 (uk)	2015-11-03	2021-05-05	Тереванс Байофарма Ар Енд Ді Айпі, Елелсі	Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CN108884077A (zh)	2016-02-25	2018-11-23	阿森纽荣股份公司	糖苷酶抑制剂
WO2017144637A1 (en)	2016-02-25	2017-08-31	Asceneuron S. A.	Acid addition salts of piperazine derivatives
JP2019506430A (ja)	2016-02-25	2019-03-07	エースニューロン・ソシエテ・アノニム	グリコシダーゼ阻害剤
US11261183B2 (en)	2016-02-25	2022-03-01	Asceneuron Sa	Sulfoximine glycosidase inhibitors
WO2018004306A1 (en) *	2016-06-30	2018-01-04	Daewoong Pharmaceutical Co., Ltd.	Pyrazolopyrimidine derivatives as kinase inhibitor
JP2019530650A (ja)	2016-08-24	2019-10-24	アークルインコーポレイテッド	アミノ−ピロロピリミジノン化合物およびその使用方法
WO2018095345A1 (zh) *	2016-11-23	2018-05-31	无锡福祈制药有限公司	一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法
MX391179B (es) *	2016-11-23	2025-03-21	Jiangsu Hengrui Medicine Co	Método de preparación e intermediario de derivado de un anillo heteroaromático de seis miembros pirrolo
US10851116B2 (en)	2017-01-20	2020-12-01	Leo Pharma A/S	Bicyclic amines as novel JAK kinase inhibitors
JP2020509004A (ja)	2017-02-27	2020-03-26	ヤンセンファーマシューティカエヌ．ベー．	Ｏｇａ阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている［１，２，４］−トリアゾロ［１，５−ａ］−ピリミジニル誘導体
TWI754019B (zh)	2017-03-09	2022-02-01	美商施萬生物製藥研發 Ip有限責任公司	含有4員雜環醯胺之jak抑制劑
CN108794480A (zh) *	2017-04-28	2018-11-13	天津药物研究院有限公司	吡咯并嘧啶类化合物、其制备方法和用途
SG11201909376TA (en)	2017-05-01	2019-11-28	Theravance Biopharma R&D Ip Llc	Crystalline forms of a jak inhibitor compound
AR111495A1 (es)	2017-05-01	2019-07-17	Theravance Biopharma R&D Ip Llc	Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CA3059785A1 (en)	2017-05-01	2018-11-08	Theravance Biopharma R&D Ip, Llc	Methods of treatment using a jak inhibitor compound
TW201920150A (zh)	2017-08-01	2019-06-01	美商施萬生物製藥研發 Ip有限責任公司	作為jak激酶抑制劑之吡唑并及三唑并雙環化合物
US11213525B2 (en)	2017-08-24	2022-01-04	Asceneuron Sa	Linear glycosidase inhibitors
MX2020004946A (es)	2017-11-03	2020-09-25	Aclaris Therapeutics Inc	Inhibidores jak de pirrolopiridina sustituidos y metodos para producir y utilizar los mismos.
CA3079848A1 (en) *	2017-11-07	2019-05-16	The Regents Of The University Of Michigan	Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
CN107857778B (zh) *	2017-11-21	2020-03-24	江苏乐斯化学有限公司	含膦酰基的α-氨基腈的制备方法
SI3733673T1 (sl) *	2017-12-28	2022-09-30	Daewoong Pharmaceutical Co., Ltd.	Oksi-fluoropiperidinski derivat kot kinazni inhibitor
KR102577242B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
US11365188B2 (en) *	2018-03-21	2022-06-21	Xibin Liao	JAK inhibitors
CN108358797A (zh) *	2018-04-20	2018-08-03	南京农业大学	一种烷基甘氨酸的合成方法
CN108640923A (zh) *	2018-07-09	2018-10-12	湖南天地恒制药有限公司	一种托法替布关键中间体的制备方法
CN112689634B (zh) *	2018-08-06	2024-07-16	莫扎制药有限公司	Smad3抑制剂
JP7591500B2 (ja) *	2018-08-10	2024-11-28	アクラリスセラピューティクス，インコーポレイテッド	ピロロピリミジンｉｔｋ阻害剤
US11795165B2 (en)	2018-08-22	2023-10-24	Asceneuron Sa	Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039027A1 (en)	2018-08-22	2020-02-27	Asceneuron S. A.	Pyrrolidine glycosidase inhibitors
US12195455B2 (en)	2018-08-22	2025-01-14	Asceneuron Sa	Succinate and fumarate acid addition salts of piperazine derivatives
WO2020039029A1 (en)	2018-08-22	2020-02-27	Asceneuron S. A.	Spiro compounds as glycosidase inhibitors
JP7383696B2 (ja)	2018-09-04	2023-11-20	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	Ｊａｋ阻害剤としての５員～７員の複素環アミド
BR112021004052A2 (pt)	2018-09-04	2021-05-25	Theravance Biopharma R&D Ip, Llc	amidas de dimetil-amino azetidina como inibidores de jak
WO2020051135A1 (en)	2018-09-04	2020-03-12	Theravance Biopharma R&D Ip, Llc	Process for preparing jak inhibitors and intermediates thereof
WO2020067887A1 (en)	2018-09-24	2020-04-02	Erasmus University Medical Center Rotterdam	Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
JP6944496B2 (ja) *	2018-10-22	2021-10-06	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
CA3113667A1 (en)	2018-10-29	2020-05-07	Theravance Biopharma R&D Ip, Llc	2-azabicyclo hexane compound as jak inhibitor
EP3914348A1 (en)	2019-01-23	2021-12-01	Theravance Biopharma R&D IP, LLC	Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
KR102737181B1 (ko) *	2019-03-14	2024-12-02	상하이 시너지 파마슈티컬 사이언시스 코., 엘티디.	Jak 억제제 및 그 제조방법과 의약분야에서의 응용
WO2020198583A1 (en)	2019-03-27	2020-10-01	Insilico Medicine Ip Limited	Bicyclic jak inhibitors and uses thereof
PH12021552036A1 (en)	2019-05-02	2022-05-23	Aclaris Therapeutics Inc	Substituted pyrrolopyridines as jak inhibitors
EP3969458A4 (en)	2019-05-13	2023-05-17	Borah, Inc.	CHEMICAL COMPOUNDS
BR112021022682A2 (pt)	2019-05-14	2022-02-22	Provention Bio Inc	Métodos e composições para prevenir diabetes do tipo 1
CN110183455B (zh) *	2019-06-18	2021-04-20	中国医科大学	氮杂双环[3.2.1]辛-3-酮类化合物及其制备方法与其用途
CN112430235B (zh) *	2019-08-26	2024-04-05	东莞市东阳光仿制药研发有限公司	一种pf-06651600中间体的制备方法
WO2021062163A1 (en)	2019-09-27	2021-04-01	Disc Medicine, Inc.	Methods for treating myelofibrosis and related conditions
KR102228668B1 (ko)	2019-10-08	2021-03-17	(주)부흥산업사	메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법
MX2022005882A (es)	2019-11-14	2022-06-14	Pfizer	Combinaciones de 1-(((2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2- il)metoxi)-7-metoxiisoquinolin-6-carboxamida y formas de dosis orales.
CN112824381B (zh) *	2019-11-21	2024-04-26	广东东阳光药业股份有限公司	一种哌啶胺的制备方法
CN113121539A (zh) *	2019-12-31	2021-07-16	江苏艾立康医药科技有限公司	一种pf06651600的制备方法
CN113121413B (zh) *	2019-12-31	2024-04-09	江苏艾立康医药科技有限公司	一种jak3酶抑制剂关键中间体的制备方法
BR112022010101A2 (pt) *	2019-12-31	2022-09-06	Pfizer R&D Uk Ltd	Formulações em comprimido e cápsula de liberação imediata estáveis de 1-((2s,5r)-5-((7h-pirrol[2,3-d]pirimidin-4-il)amino)-2-metilpiperidin-1-il)prop-2-en-1-ona
CN111138361B (zh) *	2020-01-03	2022-05-06	中国医科大学	取代苯氧基-2-氮杂双环[3.2.1]辛烷类化合物及其制备方法和应用
CN115244055B (zh) *	2020-01-21	2024-09-03	江苏先声药业有限公司	嘧啶并五元环类衍生物及其应用
US20230126204A1 (en) *	2020-02-03	2023-04-27	Boehringer Ingelheim International Gmbh	[1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
TW202144343A (zh)	2020-03-02	2021-12-01	美商施萬生物製藥研發 Ip有限責任公司	Jak抑制劑化合物之結晶水合物
WO2021198980A1 (en)	2020-04-04	2021-10-07	Pfizer Inc.	Methods of treating coronavirus disease 2019
CA3177830A1 (en)	2020-05-13	2021-11-18	Maria BECONI	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US12006366B2 (en)	2020-06-11	2024-06-11	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
CN114835715B (zh) *	2020-06-15	2024-04-05	江苏艾立康医药科技有限公司	Pf-06651600马来酸盐及其制备方法
CN111620880B (zh) *	2020-06-15	2022-06-10	江苏艾立康医药科技有限公司	Pf-06651600 dl-酒石酸盐，晶型及其制备方法
WO2022002210A1 (zh) *	2020-07-02	2022-01-06	南京明德新药研发有限公司	嘧啶并吡咯基类氘代化合物
WO2022012587A1 (zh) *	2020-07-14	2022-01-20	苏州晶云药物科技股份有限公司	丙烯酮类化合物的丙二酸盐晶型及其制备方法
CN111995623A (zh) *	2020-08-18	2020-11-27	上海毕得医药科技有限公司	一种7-溴-4-氯-1-甲基-1H-咪唑并[4,5-c]吡啶的合成方法
KR102473645B1 (ko)	2020-08-28	2022-12-05	(주)부흥산업사	(2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법
CN113061137B (zh) *	2021-04-02	2022-08-02	广西医科大学	含氮杂环衍生物或其药学上可接受的盐和用途
CA3223194A1 (en)	2021-06-25	2022-12-29	Theravance Biopharma R&D Ip, Llc	Imidazolo indazole compounds as jak inhibitors
CN113429427A (zh) *	2021-07-05	2021-09-24	湖南南新制药股份有限公司	杂环化合物及其制备方法和药物用途
WO2023025182A1 (zh) *	2021-08-25	2023-03-02	杭州禹泓医药科技有限公司	一种芳杂环类化合物、含其的药物组合物及其应用
WO2023029943A1 (zh) *	2021-09-03	2023-03-09	星药科技(北京)有限公司	一种芳杂环化合物及其制备方法和用途
WO2023151069A1 (zh) *	2022-02-14	2023-08-17	湖南南新制药股份有限公司	吡咯并[2,3-d]六元杂芳环衍生物、其制备方法和药物用途
AU2023364628A1 (en)	2022-10-18	2025-04-03	Pfizer Inc.	Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
EP4604955A1 (en)	2022-10-18	2025-08-27	Pfizer Inc.	Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024150110A1 (en)	2023-01-11	2024-07-18	Pfizer Inc.	Compositions and methods for the treatment and/or prevention of type 1 diabetes
CN116120347B (zh) *	2023-01-18	2024-08-23	杭州禹泓医药科技有限公司	芳杂环类化合物的晶型、其组合物、制备方法及其应用
CN116496280B (zh) *	2023-06-25	2023-09-08	北京科翔中升医药科技有限公司	氘代丙烯酰胺类jak3抑制剂药物及用途
WO2025146702A1 (en) *	2024-01-03	2025-07-10	Msn Laboratories Private Limited, R&D Center	Solid state forms of 1-{(2s,5r)-2-methyl-5-[(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino] piperidine-1-yl}prop-2-en-1-one 4-methylbenzene-1-sulfonic acid
WO2025181247A1 (en) *	2024-02-28	2025-09-04	Almirall, S.A.	Heterobicyclic derivatives as itk inhibitors
WO2025257773A1 (en)	2024-06-11	2025-12-18	Assia Chemical Industries Ltd.	Processes for the preparation of ritlecitinib and intermediates thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW505646B (en)	1998-06-19	2002-10-11	Pfizer Prod Inc	Pyrrolo [2,3-d] pyrimidine compounds
PA8474101A1 (es) *	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
PT1382339E (pt)	1999-12-10	2008-02-06	Pfizer Prod Inc	Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
ES2257410T3 (es) *	2000-06-26	2006-08-01	Pfizer Products Inc.	Compuestos de pirrolo(2,3-d)pirimidina como agentes inmunosupresores.
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
BR0316470A (pt)	2002-11-21	2005-10-11	Pfizer Prod Inc	Derivados de 3-amino-piperadina e métodos de preparação
AR054416A1 (es) *	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP2251341A1 (en)	2005-07-14	2010-11-17	Astellas Pharma Inc.	Heterocyclic Janus kinase 3 inhibitors
BRPI0613876A2 (pt)	2005-07-29	2011-02-15	Pfizer Prod Inc	derivados de pirrolo [2,3-d] pirimidina; seus intermediários e sìntese
WO2007062459A1 (en)	2005-11-29	2007-06-07	Cytopia Research Pty Ltd	Selective kinase inhibitors based on pyridine scaffold
SI3184526T1 (sl)	2005-12-13	2019-03-29	Incyte Holdings Corporation	Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
PL2529621T3 (pl)	2006-09-22	2017-06-30	Pharmacyclics Llc	Inhibitory kinazy tyrozynowej brutona
JO3041B1 (ar)	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
EP2328890B1 (en)	2008-08-06	2012-01-25	Pfizer Inc.	6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
NZ603495A (en)	2008-09-05	2014-05-30	Celgene Avilomics Res Inc	Algorithm for designing irreversible inhibitors
PE20110828A1 (es)	2008-10-31	2011-11-22	Genentech Inc	Compuestos de pirazolopirimidina como inhibidores de jak
WO2010063634A1 (en)	2008-12-05	2010-06-10	F. Hoffmann-La Roche Ag	Pyrrolopyrazinyl urea kinase inhibitors
JOP20190231A1 (ar)	2009-01-15	2017-06-16	Incyte Corp	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
EP2440559B1 (en) *	2009-05-05	2018-01-10	Dana-Farber Cancer Institute, Inc.	Egfr inhibitors and methods of treating disorders
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2881034B1 (en)	2009-06-30	2020-06-10	Edwards Lifesciences Corporation	Monitoring and displaying a patient's status
UA110324C2 (en)	2009-07-02	2015-12-25	Genentech Inc	Jak inhibitory compounds based on pyrazolo pyrimidine
CN102574857B (zh) *	2009-07-08	2015-06-10	利奥制药有限公司	作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物
US8486355B2 (en)	2009-08-07	2013-07-16	Metaleach Limited	Method for leaching cobalt from oxidised cobalt ores
US8785440B2 (en)	2009-09-04	2014-07-22	Biogen Idec Ma, Inc.	Bruton's tyrosine kinase inhibitors
ES2642109T3 (es)	2009-12-09	2017-11-15	Agios Pharmaceuticals, Inc.	Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
CN103003281A (zh) *	2010-05-20	2013-03-27	弗·哈夫曼-拉罗切有限公司	作为JAK和SYK抑制剂的吡咯并[2，3-b]吡嗪-7-甲酰胺衍生物和它们的用途
TW201204732A (en)	2010-07-09	2012-02-01	Leo Pharma As	Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
WO2012054364A2 (en) *	2010-10-22	2012-04-26	Merck Sharp & Dohme Corp.	Bicyclic diamines as janus kinase inhibitors
EP2788000B1 (en) *	2011-12-06	2018-05-30	Merck Sharp & Dohme Corp.	Pyrrolopyrimidines as janus kinase inhibitors
ES2682755T3 (es)	2011-12-21	2018-09-21	Jiangsu Hengrui Medicine Co. Ltd.	Derivado del anillo heteroarilo de seis miembros de pirrol, método de preparación del mismo y sus usos medicinales
MX2015002887A (es) *	2012-09-06	2015-07-06	Plexxikon Inc	Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
WO2014075392A1 (en)	2012-11-16	2014-05-22	Merck Sharp & Dohme Corp.	Purine inhibitors of human phosphatidylinositol 3-kinase delta
CN104853754A (zh)	2012-11-20	2015-08-19	普林斯匹亚生物制药公司	作为jak3抑制剂的氮杂吲哚衍生物
CN103896946B (zh) *	2012-12-28	2018-04-03	浙江导明医药科技有限公司	用于预防及治疗多种自身免疫疾病的新化合物
EP3318565B1 (en) *	2013-12-05	2021-04-14	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
WO2015178955A1 (en) *	2014-05-19	2015-11-26	Eternity Bioscience Inc.	Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors

2014
- 2014-11-20 EP EP17200940.9A patent/EP3318565B1/en active Active
- 2014-11-20 ES ES14816404.9T patent/ES2654051T3/es active Active
- 2014-11-20 PL PL14816404T patent/PL3077395T3/pl unknown
- 2014-11-20 GE GEAP201414164A patent/GEP20186840B/en unknown
- 2014-11-20 MD MDA20160058A patent/MD4649C1/ro active IP Right Grant
- 2014-11-20 ME MEP-2017-275A patent/ME02883B/me unknown
- 2014-11-20 TN TN2016000227A patent/TN2016000227A1/fr unknown
- 2014-11-20 AU AU2014358792A patent/AU2014358792C1/en active Active
- 2014-11-20 BR BR112016012262-3A patent/BR112016012262B1/pt active IP Right Grant
- 2014-11-20 PE PE2016000723A patent/PE20161246A1/es unknown
- 2014-11-20 MX MX2016007156A patent/MX368464B/es active IP Right Grant
- 2014-11-20 UA UAA201606072A patent/UA117040C2/uk unknown
- 2014-11-20 RS RS20210657A patent/RS61897B9/sr unknown
- 2014-11-20 PT PT172009409T patent/PT3318565T/pt unknown
- 2014-11-20 SI SI201430511T patent/SI3077395T1/en unknown
- 2014-11-20 SI SI201431829T patent/SI3318565T1/sl unknown
- 2014-11-20 RS RS20180008A patent/RS56728B1/sr unknown
- 2014-11-20 KR KR1020167017571A patent/KR101930603B1/ko active Active
- 2014-11-20 CN CN201480074974.2A patent/CN106061973B/zh active Active
- 2014-11-20 AP AP2016009269A patent/AP2016009269A0/en unknown
- 2014-11-20 NZ NZ720092A patent/NZ720092A/en unknown
- 2014-11-20 LT LTEP14816404.9T patent/LT3077395T/lt unknown
- 2014-11-20 DK DK14816404.9T patent/DK3077395T3/en active
- 2014-11-20 EP EP14816404.9A patent/EP3077395B1/en active Active
- 2014-11-20 CN CN201710579812.XA patent/CN107417684A/zh active Pending
- 2014-11-20 LT LTEP17200940.9T patent/LT3318565T/lt unknown
- 2014-11-20 HR HRP20171846TT patent/HRP20171846T1/hr unknown
- 2014-11-20 DK DK17200940.9T patent/DK3318565T3/da active
- 2014-11-20 JP JP2016536110A patent/JP6192839B2/ja active Active
- 2014-11-20 HU HUE17200940A patent/HUE054560T2/hu unknown
- 2014-11-20 CU CU2016000077A patent/CU24396B1/es unknown
- 2014-11-20 MY MYPI2016702037A patent/MY187446A/en unknown
- 2014-11-20 CA CA2932425A patent/CA2932425C/en active Active
- 2014-11-20 MA MA39092A patent/MA39092B1/fr unknown
- 2014-11-20 ES ES17200940T patent/ES2871524T3/es active Active
- 2014-11-20 EA EA201600373A patent/EA030472B1/ru unknown
- 2014-11-20 PL PL17200940T patent/PL3318565T3/pl unknown
- 2014-11-20 PT PT148164049T patent/PT3077395T/pt unknown
- 2014-11-20 CR CR20160250A patent/CR20160250A/es unknown
- 2014-11-20 HU HUE14816404A patent/HUE035264T2/hu unknown
- 2014-11-20 WO PCT/IB2014/066202 patent/WO2015083028A1/en not_active Ceased
- 2014-12-03 US US14/559,294 patent/US9617258B2/en active Active
- 2014-12-03 UY UY0001035861A patent/UY35861A/es not_active Application Discontinuation
- 2014-12-04 AR ARP140104517A patent/AR099363A1/es active IP Right Grant
- 2014-12-04 TW TW103142238A patent/TWI548636B/zh active
2015
- 2015-04-23 NO NO15721089A patent/NO3134430T3/no unknown
2016
- 2016-05-20 PH PH12016500938A patent/PH12016500938A1/en unknown
- 2016-05-20 CL CL2016001216A patent/CL2016001216A1/es unknown
- 2016-06-03 GT GT201600098A patent/GT201600098A/es unknown
- 2016-06-03 SV SV2016005209A patent/SV2016005209A/es unknown
- 2016-06-03 DO DO2016000124A patent/DOP2016000124A/es unknown
- 2016-06-03 NI NI201600075A patent/NI201600075A/es unknown
- 2016-06-05 IL IL246038A patent/IL246038B/en active IP Right Grant
2017
- 2017-03-01 US US15/446,500 patent/US11111242B2/en active Active
- 2017-08-08 JP JP2017152997A patent/JP2018008996A/ja active Pending
- 2017-12-18 CY CY20171101325T patent/CY1119778T1/el unknown
2021
- 2021-05-11 CY CY20211100402T patent/CY1124793T1/el unknown
- 2021-05-13 HR HRP20210770TT patent/HRP20210770T1/hr unknown
- 2021-08-04 US US17/393,463 patent/US12077533B2/en active Active
2023
- 2023-10-03 NL NL301245C patent/NL301245I2/nl unknown
- 2023-11-03 FR FR23C1042C patent/FR23C1042I2/fr active Active
- 2023-11-14 HU HUS2300040C patent/HUS2300040I1/hu unknown
- 2023-11-22 FI FIC20230035C patent/FIC20230035I1/fi unknown
- 2023-12-13 LT LTPA2023537C patent/LTC3077395I2/lt unknown
2024
- 2024-01-09 NO NO2024001C patent/NO2024001I1/no unknown
- 2024-02-09 CY CY2024002C patent/CY2024002I2/el unknown
- 2024-07-15 US US18/772,655 patent/US20250134869A1/en active Pending

Also Published As

Publication number	Publication date
LT3318565T (lt)	2021-06-25
PH12016500938B1 (en)	2016-06-27
CR20160250A (es)	2016-09-19
EP3318565B1 (en)	2021-04-14
SI3077395T1 (en)	2018-03-30
MX368464B (es)	2019-10-02
JP2018008996A (ja)	2018-01-18
CN106061973A (zh)	2016-10-26
IL246038A0 (en)	2016-08-02
RS61897B1 (sr)	2021-06-30
US20250134869A1 (en)	2025-05-01
DOP2016000124A (es)	2016-10-31
FIC20230035I1 (fi)	2023-11-22
MA39092A1 (fr)	2018-06-29
MA39092B1 (fr)	2018-09-28
ES2871524T3 (es)	2021-10-29
FR23C1042I2 (fr)	2024-11-15
ME02883B (me)	2018-04-20
PT3318565T (pt)	2021-05-28
CL2016001216A1 (es)	2017-01-20
CU20160077A7 (es)	2017-01-10
AR099363A1 (es)	2016-07-20
CY1124793T1 (el)	2022-11-25
SV2016005209A (es)	2018-04-11
EA201600373A1 (ru)	2016-10-31
CA2932425A1 (en)	2015-06-11
KR101930603B1 (ko)	2018-12-18
SI3318565T1 (sl)	2021-07-30
HRP20210770T1 (hr)	2021-06-25
EP3077395B1 (en)	2017-11-15
CU24396B1 (es)	2019-04-04
BR112016012262B1 (pt)	2021-04-13
DK3318565T3 (da)	2021-05-25
RS61897B9 (sr)	2021-09-30
HUS2300040I1 (hu)	2023-12-28
JP2016539137A (ja)	2016-12-15
MD4649B1 (ro)	2019-09-30
NO2024001I1 (no)	2024-01-09
US20150158864A1 (en)	2015-06-11
ES2654051T3 (es)	2018-02-12
US20170247372A1 (en)	2017-08-31
LTC3077395I2 (nl)	2025-09-10
PH12016500938A1 (en)	2016-06-27
TW201524977A (zh)	2015-07-01
AU2014358792B2 (en)	2017-06-08
MY187446A (en)	2021-09-22
MD4649C1 (ro)	2020-04-30
TWI548636B (zh)	2016-09-11
AP2016009269A0 (en)	2016-06-30
UY35861A (es)	2015-07-31
EP3077395A1 (en)	2016-10-12
JP6192839B2 (ja)	2017-09-06
CY1119778T1 (el)	2018-06-27
LTPA2023537I1 (nl)	2024-01-10
RS56728B1 (sr)	2018-03-30
US11111242B2 (en)	2021-09-07
HUE054560T2 (hu)	2021-09-28
MX2016007156A (es)	2016-07-21
CY2024002I1 (el)	2024-09-20
CN106061973B (zh)	2019-07-09
MD20160058A2 (ro)	2016-11-30
AU2014358792A1 (en)	2016-06-02
NZ720092A (en)	2019-05-31
DK3077395T3 (en)	2018-01-02
KR20160092012A (ko)	2016-08-03
BR112016012262A2 (pt)	2020-06-30
CA2932425C (en)	2018-07-17
AU2014358792C1 (en)	2021-08-26
WO2015083028A1 (en)	2015-06-11
PL3077395T3 (pl)	2018-04-30
EA030472B1 (ru)	2018-08-31
GT201600098A (es)	2019-10-17
NI201600075A (es)	2016-08-09
CY2024002I2 (el)	2024-09-20
US12077533B2 (en)	2024-09-03
CA2932425E (en)	2015-06-11
FR23C1042I1 (fr)	2023-12-29
US20230009153A1 (en)	2023-01-12
PT3077395T (pt)	2018-01-03
LT3077395T (lt)	2018-02-12
HUE035264T2 (hu)	2018-05-02
TN2016000227A1 (fr)	2017-10-06
PL3318565T3 (pl)	2021-10-04
US9617258B2 (en)	2017-04-11
UA117040C2 (uk)	2018-06-11
EP3318565A1 (en)	2018-05-09
HRP20171846T1 (hr)	2018-01-12
CN107417684A (zh)	2017-12-01
IL246038B (en)	2020-10-29
PE20161246A1 (es)	2016-11-25
NO3134430T3 (nl)	2018-08-18
GEP20186840B (en)	2018-04-10

Publication	Publication Date	Title
NL301341I2 (nl)	2025-10-02	eplontersen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301245I2 (nl)	2023-11-20	Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301161I2 (nl)	2022-04-06	zanubrutinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301155I2 (nl)	2022-02-23	abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301327I2 (nl)	2025-07-17	Belzutifan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder belzutifan
NL301238I2 (nl)	2023-10-04	Deucravacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301149I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301329I2 (nl)	2025-09-09	Lazertinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301006I2 (nl)	2020-04-14	Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301279I2 (nl)	2024-08-01	Adagrasib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301342I2 (nl)	2025-11-10	Elafibranor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301292I2 (nl)	2024-10-30	Iptacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301253I2 (nl)	2024-01-10	mavacamten of een farmaceutisch aanvaardbaar zout daarvan
NL301326I2 (nl)	2025-07-31	imetelstat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301224I2 (nl)	2023-08-16	Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301276I2 (nl)	2024-06-24	omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan
NL301131I2 (nl)	2021-10-25	pemigatinib of een farmaceutisch aanvaardbaar zout daarvan
NO2022010I1 (no)	2022-04-07	ripretinib, or a pharmaceutically acceptable salt thereof
NL301201I2 (nl)	2022-12-07	Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride
NO2021041I1 (no)	2021-09-20	remimazolam or a pharmaceutically acceptable salt thereof
NL301047I2 (nl)	2023-08-01	fosnetupitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder fosnetupitantchloridehydrochloride
NL301260I2 (nl)	2024-03-25	Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL300980I1 (nl)	2019-04-24	Doravirine, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300947I2 (nl)	2018-09-26	Bictegravir of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bictegravirnatrium
ZA201905426B (en)	2022-07-27	Drug combinations